Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,506.48
(
-1.51%
)
US TECH 100
23,470.00
(
-1.06%
)
Dow Jones
45,577.47
(
-0.96%
)
Brent Oil
106.93
(
0.00%
)
Bitcoin
70,434.15
(
-0.12%
)
News Focus
News Focus
Post# of 257265
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122806
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: None

Friday, 06/27/2014 3:38:16 PM

Friday, June 27, 2014 3:38:16 PM

Post# of 257265
GILD submits Japan NDA for Sovaldi/ribavirin in GT2 patients:

http://investors.gilead.com/phoenix.zhtml?c=69964&p=irol-newsArticle&ID=1943231&highlight

GT2 is a common variant in Japan, comprising about 25% of the HCV population there. The proposed treatment duration is 12 weeks (the same duration as the FDA label for Sovaldi/ribavirin in GT2).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today